- The disease
- Clostridioides difficile infection (CDI) is a bacterial infection of the colon caused by the spore-forming bacterium Clostridioides difficile, which produces toxins that damage the gut lining and cause diarrhoea. CDI is strongly associated with antibiotic use, which disrupts the normal gut microbiome. Recurrence is a major clinical problem: a meaningful proportion of patients who clear an initial infection experience one or more repeat episodes. Severe or recurrent CDI can be life-threatening, particularly in elderly or immunocompromised patients.
- What the asset is trying to do
- IMM-529 is an oral hyperimmune bovine colostrum product. Hyperimmune colostrum is produced by immunising cows with target antigens so that the resulting colostrum is enriched with antibodies directed at those antigens. In the case of IMM-529, the product is formulated to carry antibodies targeting C. difficile toxins, with the intent of neutralising toxin activity within the gut. Unlike systemic antibiotics or intravenous antibody therapies, IMM-529 is administered orally, delivering antibodies directly to the gastrointestinal tract.
- What the trial is measuring, and why it matters
- The prior terminated Phase 1/2 trial (NCT03065374) enrolled subjects with C. difficile infection or recurrence and included a placebo comparator arm (per ClinicalTrials.gov NCT03065374). The planned Phase 2 randomised controlled trial (RCT) is described in company announcements as enrolling up to 60 subjects in Australia (per Immuron Strategic Update and HY26 Results, ASX announcement 25 February 2026). Typical endpoints in CDI trials include rates of clinical cure, sustained clinical response, and recurrence within a defined follow-up window; the specific primary and secondary endpoints for the new Phase 2 RCT have not been disclosed in the available input data.
- Efficacy benchmarks in this setting
- In the CDI setting, bezlotoxumab (Zinplava), a monoclonal antibody targeting C. difficile toxin B, demonstrated a recurrence rate of 17% versus 28% for placebo (absolute risk reduction of approximately 10 percentage points) in the MODIFY I and MODIFY II Phase 3 trials (Wilcox et al, New England Journal of Medicine, 2017). Fidaxomicin, an approved antibiotic for CDI, showed clinical cure rates of approximately 88% versus 86% for vancomycin, with lower recurrence rates for the non-hypervirulent strain in the DIFICID trial (Louie et al, New England Journal of Medicine, 2011). IMM-529 is in early-stage development; the patient numbers, trial design, and statistical power of the current programme differ substantially from pivotal trials, and any figures from early-stage studies are not statistically comparable to the above approved-therapy benchmarks.